IP Library Granted Patent US 7,932,053
Granted Patent B2
US 7,932,053 · App. 11/547,822 · Granted Apr 26, 2011

Method for preparing modified collagen outside a host cell

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,932,053
App. No.
11/547,822
Granted
Apr 26, 2011
Kind
B2
Abstract

The present invention relates to a method for preparing a modified folded protein, comprising modifying unfolded a-chains comprising a collagenous amino acid sequence and thereafter folding at least part of the modified a-chains into a quaternary protein structure, in particular a helical protein structure. The invention allows for an attractive alternative for making recombinant proteins, such as recombinant collagens and the like, which may be used in a variety of biomedical and other applications.

Claims (19)

1. A method for the in vitro production of a modified collagenous protein, comprising

(a) unfolding folded collagen α-chains comprising an association domain to obtain unfolded collagen α-chains;

(b) modifying the unfolded α-chains by adding modifying enzymes; and

(c) folding the modified α-chains into a triple helical structure;

wherein none of steps (a)-(c) is performed intracellularly; and

wherein said association domains comprise one or more interchain crosslinks linking the collagen α-chains together; or

wherein the association domains comprise amino acid sequences that reassociate after unfolding; or

wherein the association domains comprise amino sequences by which the collagen α-chains remain bound to each other during unfolding of the remainder of the collagen α-chains; and

wherein said modifying enzymes modify the amino acid side chains of the α-chains.

2. The method of claim 1 , wherein the modifying is by one or more enzymes selected from the group consisting of prolyl hydroxylases, lysyl hydroxylases, lysyl oxidases, hydroxylysyl-galactosyltransferases and galactosylhydroxylysyl-glucosyltransferases.

3. The method of claim 2 , wherein the modifying comprises hydroxylating proline by a prolyl-3-hydroxylase, or a prolyl-4-hydroxylase or a combination thereof.

4. The method of claim 2 , wherein the modifying comprises hydroxylating lysine by a helical lysyl hydroxylase, or a telopeptide lysyl hydroxylase or a combination thereof.

5. The method of claim 2 , wherein the modifying comprises glycosylating hydroxylysine by a lysyl hydroxylase.

6. The method of claim 2 , wherein the modifying comprises oxidatively deaminating the ε-amino group of lysine or hydroxylysine by a lysyl oxidase.

7. The method of claim 2 , wherein said enzymes are recombinant proteins synthesized by prokaryotic or eukaryotic cells.

8. The method of claim 1 , wherein said interchain crosslinks are Cys-Cys bridges wherein said Cys residues are present in the triple helical part of the α-chain and/or in the telopeptide part of the α-chain and/or in the propeptide part of the α-chain and/or at the start of the α-chain and/or at the end of the α-chain.

9. The method of claim 1 , wherein said amino acid sequences comprise SEQ ID NO:1.

10. The method of claim 1 , wherein said amino acid sequences are present in the triple helical part of the α-chains and/or in the telopeptide part of the α-chain and/or in the propeptide part of the α-chain and/or at the start of the α-chain and/or at the end of the α-chain.

11. The method of claim 1 , wherein said crosslinks are formed by at least two Cys residues per collagen α-chain.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Jan 18, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
Reel/Frame 066167/0462 →
SECURITY INTEREST Recorded Nov 17, 2021
From: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.; ADRENAS THERAPEUTICS, INC.; PHOENIX TISSUE REPAIR, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058144/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.; LOTUS TISSUE REPAIR, INC.
To: PHOENIX TISSUE REPAIR, INC.
Reel/Frame 043447/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2014
From: NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJKONDERZOEK TNO
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033766/0117 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2007
From: BANK, RUDOLF ANTONIUS; ZUURMOND, ANNE-MARIE; JORE, JOHANNES PETRUS MARIA; VAN DEN HONDEL, CORNELIS ANTONIUS MARIA JACOBUS JOHANNES
To: NEDERLANDSE ORGANISATIE VOOR TOEGEPASTNATUURWETENSCHAPPELIJK ONDERZOEK TNO
Reel/Frame 019060/0070 →